Lyme Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Pages: 68 Published: March 31, 2022 Report Code: GMDGDHC22048IDB

Lyme  disease  is  a  bacterial  infection  transmitted  by  a  tick.  Lyme  disease  is  caused  by  the  bacterium  Borrelia burgdorferi. Symptoms include rash, fever, chills, fatigue, body aches and headache. Risk factors include age, gender and geographic locations.

The Lyme Disease – Drugs  In Development research report provides a comprehensive overview on the therapeutics under development for Lyme Disease,  complete  with  analysis  by  stage  of  development,  drug  target,  mechanism  of  action  (MoA),  route  of administration  (RoA)  and  molecule  type.  The  report  also  covers  the  descriptive  pharmacological  action  of  the therapeutics,  its  complete  research  and  development  history  and  latest  news  and  press  releases.  Additionally,  the report  provides  an  overview  of  key  players  involved  in  therapeutic  development  for  Lyme  Disease  and  features dormant and discontinued projects.

Key Targets in the Lyme Disease Pipeline Drugs Market

The key targets in the Lyme Disease pipeline drugs market are Outer Surface Protein A, 23S Ribosomal RNA, Borreliella burgdorferi Complement Regulator Acquiring Protein 1, Corticotropin Releasing Factor Receptor 2 and Fibronectin.

Key Targets in the Lyme Disease Pipeline Drugs Market

For more target insights, download a free report sample

Key mechanisms of action in the Lyme Disease pipeline drugs market

The key mechanisms of action in the Lyme Disease pipeline drugs market are Outer Surface Protein A inhibitor, 23S Ribosomal RNA inhibitor, Borreliella burgdorferi Complement Regulator Acquiring Protein 1 inhibitor, Corticotropin Releasing Factor Receptor 2 inhibitor and Fibronectin inhibitor.

Key mechanisms of action in the Lyme Disease pipeline drugs market

To get more insights on key MoA, download a free report sample

Key routes of administration in the Lyme Disease pipeline drugs market

The key routes of administration in the Lyme Disease  pipeline drugs market are intravenous, topical, nasal oral, parenteral, subcutaneous, and intramuscular.

Key routes of administration in the Lyme Disease pipeline drugs market

To get more insights on key RoA, download a free report sample

Key Molecule Types in the Lyme Disease Pipeline Drugs Market

The different molecule types in the Lyme Disease pipeline drugs market are small molecule, Subunit Vaccine, Monoclonal Antibody, Recombinant Vector Vaccine, Fusion Protein, and Gene Therapy, and Peptide.

Key Molecule Types in the Lyme Disease Pipeline Drugs Market

To get more insights on key molecule types, download a free report sample

Major companies in the Lyme Disease Pipeline Drugs Market

The major companies in the Lyme Disease pipeline drugs market are Flightpath BioSciences Inc, Abzyme Therapeutics LLC, Agile Sciences Inc, Applied Biotechnology Institute Inc, Artes Biotechnology GmbH, CyanVacLLC, Greffex Inc, and Inovio Pharmaceuticals Inc.

Lyme Disease Pipeline Drugs Market Overview

Key routes of administration Intravenous, Topical, Nasal Oral, Parenteral, Subcutaneous, and Intramuscular

 

Key molecule types Small Molecule, Subunit Vaccine, Monoclonal Antibody, Recombinant Vector Vaccine, Fusion Protein, Peptide, and Gene Therapy
Major companies Flightpath BioSciences Inc, Abzyme Therapeutics LLC, Agile Sciences Inc, Applied Biotechnology Institute Inc, Artes Biotechnology GmbH, CyanVacLLC, Greffex Inc, and Inovio Pharmaceuticals Inc
Key targets Outer Surface Protein A, 23S Ribosomal RNA, Borreliella burgdorferi Complement Regulator Acquiring Protein 1, Corticotropin Releasing Factor Receptor 2 and Fibronectin

 

key mechanisms of action Outer Surface Protein A inhibitor, 23S Ribosomal RNA inhibitor, Borreliella burgdorferi Complement Regulator Acquiring Protein 1 inhibitor, Corticotropin Releasing Factor Receptor 2 inhibitor and Fibronectin inhibitor

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Lyme Disease
  • The pipeline guide reviews pipeline therapeutics for Lyme Disease by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Lyme Disease therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Lyme Disease therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews the latest news related to pipeline therapeutics for Lyme Disease

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with a potentially strong product portfolio and create effective counter-strategies to gain a competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Lyme Disease
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Lyme Disease pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

Key Players

  • Abzyme Therapeutics LLC

    Agile Sciences Inc

    Applied Biotechnology Institute Inc

    Artes Biotechnology GmbH

    Cortene Inc

    CyanVac LLC

    Flightpath BioSciences Inc

    Greffex Inc

    Inovio Pharmaceuticals Inc

    Ixodes AG

    L2 Diagnostics LLC

    NovoBiotic Pharmaceuticals LLC

    Planet Biotechnology Inc

    Reven Holdings Inc

    Tarsus Pharmaceuticals Inc

    Valneva SE

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Lyme Disease – Overview

Lyme Disease – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Lyme Disease – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Lyme Disease – Companies Involved in Therapeutics Development

Abzyme Therapeutics LLC

Agile Sciences Inc

Applied Biotechnology Institute Inc

Artes Biotechnology GmbH

Cortene Inc

CyanVac LLC

Flightpath BioSciences Inc

Greffex Inc

Inovio Pharmaceuticals Inc

Ixodes AG

L2 Diagnostics LLC

NovoBiotic Pharmaceuticals LLC

Planet Biotechnology Inc

Reven Holdings Inc

Tarsus Pharmaceuticals Inc

Valneva SE

Lyme Disease – Drug Profiles

azithromycin – Drug Profile

Product Description

Mechanism Of Action

History of Events

azlocillin sodium – Drug Profile

Product Description

Mechanism Of Action

Bi-specific Monoclonal Antibody to Inhibit CRASP1 for Lyme Disease – Drug Profile

Product Description

Mechanism Of Action

History of Events

BL-400 – Drug Profile

Product Description

Mechanism Of Action

CT-38 – Drug Profile

Product Description

Mechanism Of Action

desloratadine – Drug Profile

Product Description

Mechanism Of Action

disulfiram – Drug Profile

Product Description

Mechanism Of Action

Fusion Proteins for Lyme Disease and Tick-Borne Diseases – Drug Profile

Product Description

Mechanism Of Action

History of Events

Gene Therapy to Inhibit OspA for Lyme Disease – Drug Profile

Product Description

Mechanism Of Action

hygromycin – Drug Profile

Product Description

Mechanism Of Action

History of Events

lyme borreliosis vaccine – Drug Profile

Product Description

Mechanism Of Action

lyme disease vaccine – Drug Profile

Product Description

Mechanism Of Action

lyme disease vaccine – Drug Profile

Product Description

Mechanism Of Action

Lyme disease vaccine – Drug Profile

Product Description

Mechanism Of Action

lyme disease vaccine – Drug Profile

Product Description

Mechanism Of Action

History of Events

lyme disease vaccine 2 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Monoclonal Antibodies to Inhibit Outer Surface Protein A for Lyme Disease – Drug Profile

Product Description

Mechanism Of Action

History of Events

RPOT-1003a – Drug Profile

Product Description

Mechanism Of Action

Small Molecule for Lyme Disease – Drug Profile

Product Description

Mechanism Of Action

Small Molecules for Lyme Disease – Drug Profile

Product Description

Mechanism Of Action

TP-05 – Drug Profile

Product Description

Mechanism Of Action

History of Events

VLA-15 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Lyme Disease – Dormant Projects

Lyme Disease – Product Development Milestones

Featured News & Press Releases

Feb 04, 2022: Valneva and Pfizer report further positive phase 2 data for lyme disease vaccine candidate

Sep 29, 2021: Valneva and Pfizer report positive data from Lyme disease vaccine trial

Jul 20, 2021: Pfizer and Valneva close enrolment in Phase II Lyme disease vaccine trial

Jun 16, 2021: Tarsus Pharmaceuticals initiates phase 1 Callisto trial of TP-05, a novel, oral, non-vaccine therapeutic for the prevention of lyme disease

May 04, 2021: Tarsus Pharmaceuticals announces FDA acceptance of investigational new drug application for TP-05 for Lyme disease prevention

Mar 08, 2021: Valneva and Pfizer announce initiation of phase 2 study for Lyme disease vaccine candidate

Dec 02, 2020: Valneva announces acceleration of pediatric development for lyme disease vaccine candidate

Oct 20, 2020: Valneva announces positive initial results for second phase 2 study of Lyme disease vaccine candidate VLA15

Jul 22, 2020: Valneva announces positive initial results for phase 2 study of Lyme disease vaccine candidate

Sep 30, 2019: Valneva completes recruitment for phase 2 studies of its Lyme Disease vaccine candidate VLA15

Jul 03, 2019: Valneva: Renowned Vaccinologist Dr. Stanley Plotkin to Present on VLA-15 at R&D Investor Day in New York City

Jul 01, 2019: Valneva initiates second phase 2 study for its Lyme Disease Vaccine Candidate VLA15

Jun 12, 2019: Valneva reports successful outcome of phase 2 run-in for its lyme disease vaccine candidate

Jun 11, 2019: Valneva to present Lyme Disease vaccine update at R&D Investor Day in New York City on July 9th

Apr 09, 2019: Valneva to present on Lyme vaccine candidate at the 19th World Vaccine Congress

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Lyme Disease, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Lyme Disease – Pipeline by Abzyme Therapeutics LLC, 2022

Lyme Disease – Pipeline by Agile Sciences Inc, 2022

Lyme Disease – Pipeline by Applied Biotechnology Institute Inc, 2022

Lyme Disease – Pipeline by Artes Biotechnology GmbH, 2022

Lyme Disease – Pipeline by Cortene Inc, 2022

Lyme Disease – Pipeline by CyanVac LLC, 2022

Lyme Disease – Pipeline by Flightpath BioSciences Inc, 2022

Lyme Disease – Pipeline by Greffex Inc, 2022

Lyme Disease – Pipeline by Inovio Pharmaceuticals Inc, 2022

Lyme Disease – Pipeline by Ixodes AG, 2022

Lyme Disease – Pipeline by L2 Diagnostics LLC, 2022

Lyme Disease – Pipeline by NovoBiotic Pharmaceuticals LLC, 2022

Lyme Disease – Pipeline by Planet Biotechnology Inc, 2022

Lyme Disease – Pipeline by Reven Holdings Inc, 2022

Lyme Disease – Pipeline by Tarsus Pharmaceuticals Inc, 2022

Lyme Disease – Pipeline by Valneva SE, 2022

Lyme Disease – Dormant Projects, 2022

List of Figures

List of Figures

Number of Products under Development for Lyme Disease, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Targets, 2022

Number of Products by Stage and Targets, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently Asked Questions

$2000

Can be used by individual purchaser only

$6000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.